Aging Is a Disease — And the WHO Almost Admitted It
In 2018, the WHO nearly classified aging as a disease. The pharmaceutical industry panicked. Discover why calling aging 'natural' is scientifically wrong.
The Classification That Never Was
In 2018, the World Health Organization almost classified aging as a disease. The pharmaceutical industry panicked. Here's why.
Behind closed doors in Geneva, a small group of gerontologists and policy experts proposed adding a new code to the International Classification of Diseases (ICD-11): age-related decline as a treatable medical condition. The implications were staggering — over $7 trillion in global healthcare spending would suddenly need reclassification, and drugs targeting aging could finally clear regulatory hurdles. Then, the proposal vanished from the final draft.
What the ICD-11 Almost Changed
The International Classification of Diseases, maintained by the WHO, is the global standard for diagnosing every medical condition known to humanity. When ICD-11 was being drafted, researchers pushed for a specific code that would recognize aging not as an inevitable fate, but as a progressive, multifactorial condition amenable to intervention.
“[!INSIGHT] The absence of a disease code for aging has blocked billions in research funding. Without an official ICD classification, pharmaceutical companies cannot obtain FDA or EMA approval for "anti-aging" drugs”
The proposed extension, labeled XT9T, would have classified "aging-related" as a legitimate medical descriptor. This wasn't about calling every wrinkle a symptom. It was about recognizing that the biological processes driving age-related decline — cellular senescence, mitochondrial dysfunction, epigenetic drift — are mechanistically similar to recognized diseases.
In 2019, a group of scientists including Aubrey de Grey and Bill Andrews published an open letter urging the WHO to reconsider. They argued that classifying aging as a disease would accelerate clinical trials for geroprotective interventions like rapamycin, metformin, and senolytics. The counterargument from traditionalists? "Aging is natural."
Why "Natural" Is Not a Scientific Argument
This objection collapses under scrutiny. Smallpox was natural. Tooth decay was natural. Cancer was natural — until we decided to intervene. The appeal to nature is a logical fallacy, not a biological argument.
Dr. David Sinclair, a geneticist at Harvard Medical School, has spent two decades demonstrating that aging is driven by a loss of epigenetic information — a process that can, in principle, be reversed.
“"Aging is a loss of information, not a gain of damage. And loss of information can be restored.”
Consider the data: in 2023, the global life expectancy was 73.4 years, but healthy life expectancy was only 63.3 years. That's a decade of life spent in declining health, much of it preventable if aging itself were treated as a medical condition. Japan, with the world's oldest population, spent over 11% of its GDP on healthcare in 2022 — a figure projected to hit 15% by 2040 as its citizenry continues to gray.
Who Panicked — And Why
The pharmaceutical industry's reaction to the proposed ICD-11 change was not one of enthusiasm. It was fear.
Here's the problem: if aging becomes a disease, then every drug company suddenly faces a new competitive landscape. Current blockbuster drugs for diabetes, cardiovascular disease, and neurodegeneration would be competing directly with compounds that target the root cause — aging itself. The market disruption would be existential for companies whose business models depend on treating chronic symptoms rather than preventing them.
[!NOTE] The global market for anti-aging drugs is projected to reach $93 billion by 2030, according to Grand View Research. But without ICD classification, these treatments remain in regulatory limbo, classified as supplements or off-label prescriptions rather than legitimate medical interventions.
The real opposition, however, came from geriatricians and ethicists who worried about ageism. If aging is a disease, would that stigmatize the elderly? Would insurance companies deny coverage to those who "refused treatment" for their condition? These concerns, while valid, conflate diagnosis with discrimination.
A 2022 study in Nature Aging surveyed 1,000 adults over 65. The result? 78% supported research into extending healthy lifespan, and 62% said they would take a medication proven to delay aging if it were available. The elderly, it turns out, do not view their own decline as "natural" or "inevitable." They view it as a problem to be solved.
The Pipeline Is Already Here
Despite regulatory hurdles, the science of longevity has advanced rapidly. As of 2024, there are over 200 clinical trials targeting various aspects of biological aging.
Key compounds in development:
-
Rapamycin: Originally an immunosuppressant, now shown to extend lifespan in mice by up to 25%. Human trials for aging indications are ongoing at Stanford and the Buck Institute.
-
Metformin: The world's most prescribed diabetes drug. The TAME (Targeting Aging with Metformin) trial, launched in 2023, is the first FDA-approved trial to test a drug specifically for aging outcomes.
-
Senolytics: A class of drugs that eliminate senescent "zombie" cells. Companies like Unity Biotechnology and Clearance Therapeutics are racing to bring these to market for age-related conditions like osteoarthritis and macular degeneration.
-
NAD+ precursors: Supplements like NMN and NR, popularized by Sinclair's research, aim to restore cellular energy metabolism. While consumer adoption has exploded, clinical evidence remains mixed.
[!INSIGHT] The TAME trial represents a regulatory breakthrough. By treating aging as a composite of measurable outcomes — frailty, cognitive decline, cardiovascular events — researchers are sidestepping the need for an official disease code. If successful, it could establish a new precedent for FDA approval of geroprotective drugs.
The So What: Why Classification Matters Now
The WHO's decision to exclude aging from ICD-11 was not a scientific verdict. It was a political compromise.
Every year of delay has consequences. By 2050, the number of people over 65 will double to 1.6 billion globally. Healthcare systems designed for acute illness are already buckling under the weight of chronic, age-related conditions. The economic argument for treating aging is unassailable: extending healthy lifespan by just one year could save the United States alone $38 trillion in healthcare costs, according to a 2021 study in Nature Communications.
“"We are spending trillions to treat the symptoms of aging while ignoring the disease itself. It's like treating smoke inhalation while the house burns down.”
The next revision of the ICD is scheduled for 2035. By then, the science of longevity will likely have produced multiple proven interventions. The question is whether regulation will catch up — or whether millions will die waiting for a classification code.
Conclusion
Aging meets every scientific criterion for disease: it has identifiable causes, progressive symptoms, and — increasingly — treatable mechanisms. The WHO's refusal to classify it as such reflects institutional inertia, not biological truth.
Sources: World Health Organization ICD-11 Documentation (2019); Sinclair, D. Lifespan (2019); Nature Aging, "Public attitudes toward longevity research" (2022); Nature Communications, "Economic value of targeting aging" (2021); Grand View Research, Anti-Aging Market Report (2023); TAME Trial ClinicalTrials.gov NCT04324368
